First Heartland Consultants Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 6.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 5,657 shares of the medical research company’s stock after acquiring an additional 327 shares during the period. First Heartland Consultants Inc.’s holdings in Amgen were worth $974,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the stock. Bristlecone Advisors LLC grew its position in Amgen by 3.2% in the second quarter. Bristlecone Advisors LLC now owns 16,807 shares of the medical research company’s stock worth $2,895,000 after acquiring an additional 524 shares during the period. FineMark National Bank & Trust grew its position in Amgen by 1.9% in the second quarter. FineMark National Bank & Trust now owns 28,763 shares of the medical research company’s stock worth $4,954,000 after acquiring an additional 536 shares during the period. Strs Ohio grew its position in Amgen by 4.5% in the second quarter. Strs Ohio now owns 452,065 shares of the medical research company’s stock worth $77,859,000 after acquiring an additional 19,285 shares during the period. Argyle Capital Management Inc. grew its position in Amgen by 0.3% in the second quarter. Argyle Capital Management Inc. now owns 30,684 shares of the medical research company’s stock worth $5,285,000 after acquiring an additional 100 shares during the period. Finally, Kidder Stephen W grew its position in Amgen by 3.0% in the second quarter. Kidder Stephen W now owns 2,590 shares of the medical research company’s stock worth $446,000 after acquiring an additional 75 shares during the period. Institutional investors own 78.09% of the company’s stock.
Several brokerages recently weighed in on AMGN. Royal Bank Of Canada began coverage on Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Deutsche Bank AG reiterated a “hold” rating and issued a $174.00 price objective (up from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Cann reiterated a “buy” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $186.14.
WARNING: This piece was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/21/first-heartland-consultants-inc-has-974000-position-in-amgen-inc-amgn.html.
Shares of Amgen Inc. (AMGN) opened at 188.17 on Thursday. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10. The firm has a market capitalization of $137.30 billion, a PE ratio of 17.14 and a beta of 1.35. The firm has a 50-day moving average price of $175.99 and a 200-day moving average price of $169.31.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the business posted $2.84 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, analysts forecast that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were issued a $1.15 dividend. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.44%. Amgen’s dividend payout ratio is currently 41.93%.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.